The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance.
J. E. Chaft
No relevant relationships to disclose
G. R. Oxnard
No relevant relationships to disclose
V. A. Miller
Consultant or Advisory Role - ArQule; Boehringer Ingelheim; Genentech; Pfizer; Roche
Honoraria - ArQule; Boehringer Ingelheim; Genentech; Pfizer; Roche
Research Funding - Boehringer Ingelheim; Genentech; Pfizer
M. G. Kris
Consultant or Advisory Role - Boehringer Ingelheim; Pfizer
C. S. Sima
No relevant relationships to disclose
G. J. Riely
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim